ThromboGenics will underwrite ambitions from €375M ocriplasmin deal with Alcon
This article was originally published in Scrip
ThromboGenics, the Belgian biotech company, intends to build its ophthalmology franchise with substantial help from Alcon, the eye care specialist subsidiary of Novartis. Alcon has secured the rights to market ocriplasmin outside the US for an upfront payment to the Belgian biotech worth €75 million. With a potential total deal value of €375 million the Belgian biotech could be in line to receive up to€90 million in near term milestones.